Drugs / DTPw-HBV/Hib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00158808 | Jan → Apr 2005 | haemophilus infectious disease, hepatitis B virus infection, nasopharyngeal diphtheria, pertussis +1 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTPw-HBV/Hib | “DTPw-HBVLT/Hib2.5 or DTPw-HBV/Hib10 vaccines can contribute to reducing childhood diseases through ensuring high vaccine coverage in mass vaccination programs.” PMID 20657177 ↗ Aug 2010 |
| Modality | Vaccine | “DTPw-HBVLT/Hib2.5 combination vaccine with reduced thiomersal and Hib content had equivalent immunogenicity and tolerability versus the full standard DTPw-HBV/Hib10 vaccine.” PMID 20657177 ↗ Aug 2010 |